Information about Pentostatin
Liver safety of Pentostatin
Pentostatin is associated with a low rate of serum enzyme elevations during therapy and has been linked to rare instances of severe acute liver injury with jaundice.
Mechanism of action of Pentostatin
Pentostatin (pen" toe stat' in) is a purine analogue (2'-deoxycoformycin) that is used in the treatment of hairy cell leukemia and T cell lymphomas. Pentostatin is a transition state analogue of a major intermediate in the pathway of the adenosine deaminase reaction. As a consequence, pentostatin inhibits adenosine deaminase and causes accumulation of intracellular adenosine and deoxyadenosine which cause a block DNA synthesis. This imbalance of nucleotide pools is particularly toxic to lymphocytes.
FDA approval information for Pentostatin
Dosage and administration for Pentostatin
Pentostatin is available as a solution for injection generically and under the trade name Nipent. The typical dose regimen is 4 mg/m2 given intravenously every other week for 6 months. Repeat courses are recommended only for patients who have a response and later relapse.
Side effects of Pentostatin
Common side effects include bone marrow suppression, fever, infections, nausea, vomiting, anorexia, diarrhea, headache, fatigue and skin rash. Because pentostatin tends to deplete normal T cells, opportunistic infections can occur and immunosuppression can persist for months or years after discontinuation. At high doses, pentostatin can cause severe renal and neurologic toxicity and in combination with fludarabine can cause pulmonary toxicity.